← boardnext 2026-11
DRUG
Bright Minds Biosciences Pty Ltddistress 2/10 · well-funded / low risk$73.06-3%today-24% from 52w high
Neurology 1
Lead: Prader-Willi Syndrome
Revenue
pre-revenue
Liquidity
$310M
Runway
35.6 yrs
Shares 1y
-62%
Price & events
-19.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-1.6%
1W
+12.2%
1M
-17.6%
3M
-16.0%
6M
+144.5%
1Y
+6482.0%
2Y
+238.2%
5Y
+170.6%
All
Overview
- Market Cap
- $330.53M
- Volume
- 22.80K
- 52 Week Range
- $24.36 – $95.98
- Total Shares
- 4.52M
- Float Shares
- 5.13M
- Short %
- 12.60%
- % Held by Insiders
- 12.00%
- % Held by Institutions
- 92.92%
- RVOL
- 0.07x
- Beta
- 0.10
Pipeline stages · 1 programs
BMB-101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-01HC Wainwright & Co.Buy
- 2026-05-20Piper SandlerOverweight
- 2026-04-13JefferiesBuy
- 2026-03-30BTIGBuy
- 2026-03-04HC Wainwright & Co.Buy
- 2026-02-17BTIGBuy
Competitors — Prader-Willi Syndrome
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- ACADACADIA PHARMACEUTICALS INC$4.2B · D0
- HRMYHarmony Biosciences Holdings, Inc.$2.0B · D0
- RLMDRELMADA THERAPEUTICS, INC.$511M · D6
- TNXPTonix Pharmaceuticals Holding Corp.$170M · D7
- AARDAardvark Therapeutics, Inc.$142M · D5
- PTNPALATIN TECHNOLOGIES INC$14M · D9
- SLNOSoleno Therapeutics, Inc.— · D0
Recent news
- 2026-07-23PSG Report Finds Specialty Drug Utilization is Dominant Driver of Trend, Biosimilar Adoption Reshaping the Market - Business Wire
- 2026-07-23Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - GlobeNewswire
- 2026-07-23Walleye Capital LLC Has $3.92 Million Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
- 2026-07-23Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Zacks Research - MarketBeat
- 2026-07-22Revolution Medicines’ New Drug Application for Daraxonrasib - GlobeNewswire
- 2026-07-22Transcripta Bio Announces $24 Million in Funding to Advance AI-Powered Drug Discovery Platform for Neurological and Neuromuscular Diseases - Business Wire
- 2026-07-22All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
- 2026-07-22Cheiron Raises $8M Seed Led by Menlo Ventures to Build the Operating System for Drug Programs - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.